. 2020 Jan 16;10:428. doi: 10.1038/s41598-019-57366-y

Table 1.

Comparison of clinical characteristics and results of laboratory tests between NLR tertile groups.

Variables	T1 (n = 65)	T2 (n = 64)	T3 (n = 65)	P-value^*
Variables	T1 (n = 65)	T2 (n = 64)	T3 (n = 65)	Overall	T1 vs. T2	T1 vs. T3	T2 vs. T3
NLR^a	1.14 ± 0.26	1.77 ± 0.19	2.91 ± 0.85	<0.001	<0.001	<0.001	<0.001
Male/Female^b	32/33	38/26	39/26	0.381	NS	NS	NS
Age at onset (years)^a	61.5 ± 12.2	58.0 ± 9.64	63.9 ± 11.6	0.012	NS	NS	0.009
BMI (kg/m²)^a	22.8 ± 2.51	22.9 ± 2.80	22.1 ± 3.28	0.282	NS	NS	NS
Onset region^b				0.071	NS	NS	NS
Bulbar	23	11	17
Limb	42	52	47
Others	0	1	1
From onset to diagnosis (months)^a	13.7 ± 7.93	14.0 ± 9.22	13.4 ± 8.81	0.906	NS	NS	NS
ALSFRS-R^a	39.7 ± 6.55	38.6 ± 5.67	38.5 ± 6.18	0.562	NS	NS	NS
Progression rate^c	0.56 (0.30–0.80)	0.61 (0.33–1.21)	0.66 (0.40–1.27)	0.142	NS	NS	NS
FVC^b				0.017	NS	NS	0.024
≥80%	20	27	16
<80%	23	17	34
Not performed	22	20	15
Riluzole use^b	9	17	16	0.166	NS	NS	NS
Total cholesterol (mg/dL)^a	188 ± 38.1	191 ± 36.7	185 ± 32.0	0.631	NS	NS	NS
Albumin (g/dL)^a	4.15 ± 0.26	4.15 ± 0.26	4.09 ± 0.32	0.388	NS	NS	NS
Creatinine (mg/dL)^a	0.67 ± 0.15	0.69 ± 0.14	0.69 ± 0.16	0.678	NS	NS	NS
Uric acid (mg/dL)^a	4.89 ± 1.47	5.08 ± 1.50	4.70 ± 1.37	0.330	NS	NS	NS
CRP (mg/dL)^c	0.07 (0.02–0.14)	0.06 (0.02–0.12)	0.07 (0.02–0.17)	0.242	NS	NS	NS
Survival duration (months)^c	37.0 (24.0–56.0)	32.5 (19.5–51.2)	22.0 (17.0–38.0)	NA	NA	NA	NA

^aData are expressed as mean ± standard deviation. ^bData are expressed as the number of patients. ^cData are expressed as median (1Q–3Q).

^*One-way ANOVA with Tukey’s HSD tests for continuous variables or Pearson’s chi-square tests with Bonferroni correction for categorical variables.

Abbreviations: NLR = neutrophil-to-lymphocyte ratio; BMI = body mass index; ALSFRS-R = ALS functional rating scale-revised; FVC = forced vital capacity; CRP = C-reactive protein; NS = not significant (p-value ≥ 0.1); NA = not applicable.